Signaturefd LLC lifted its stake in Becton Dickinson and Co (NYSE:BDX) by 4.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,785 shares of the medical instruments supplier’s stock after acquiring an additional 84 shares during the quarter. Signaturefd LLC’s holdings in Becton Dickinson and were worth $450,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of BDX. Harvest Group Wealth Management LLC bought a new stake in Becton Dickinson and in the first quarter worth $25,000. Hexavest Inc. bought a new stake in Becton Dickinson and in the second quarter worth $28,000. Lipe & Dalton bought a new stake in Becton Dickinson and in the second quarter worth $28,000. Pinnacle Financial Partners Inc. bought a new stake in Becton Dickinson and in the first quarter worth $29,000. Finally, RPG Investment Advisory LLC bought a new stake in Becton Dickinson and in the first quarter worth $32,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.
BDX stock traded up $4.15 during mid-day trading on Tuesday, reaching $253.31. 32,741 shares of the stock traded hands, compared to its average volume of 1,066,327. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87. The stock has a 50-day simple moving average of $251.93. The company has a market cap of $68.66 billion, a price-to-earnings ratio of 22.99, a PEG ratio of 1.85 and a beta of 1.11.
The company also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.
In other Becton Dickinson and news, EVP Simon D. Campion sold 2,903 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $236.94, for a total transaction of $687,836.82. Following the completion of the sale, the executive vice president now directly owns 9,408 shares in the company, valued at $2,229,131.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Roland Goette sold 1,717 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $249.88, for a total transaction of $429,043.96. Following the completion of the sale, the executive vice president now owns 19,966 shares of the company’s stock, valued at approximately $4,989,104.08. The disclosure for this sale can be found here. Insiders have sold 24,529 shares of company stock valued at $5,836,116 over the last 90 days. Corporate insiders own 0.12% of the company’s stock.
A number of equities research analysts recently issued reports on BDX shares. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Piper Jaffray Companies decreased their price objective on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. UBS Group decreased their price objective on shares of Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, May 10th. Morgan Stanley upped their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a report on Tuesday, July 16th. Finally, Wells Fargo & Co decreased their price target on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a report on Monday, May 13th. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $264.27.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Trading Options- What is a Strangle?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.